Trial Profile
Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical trial. Eficacia de la combinación de simvastatina y rifaximina en pacientes con cirrosis descompensada para prevenir el desarrollo de ACLF: ensayo clínico multicéntrico aleatorizado, doble-ciego, controlado con placebo.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Simvastatin (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- 25 Sep 2023 This trial has been completed in Spain (Global end date: 1 Dec 2022).
- 30 Mar 2023 This trial has been completed in France (End Date: 1 Dec 2022) according to European Clinical Trials Database record.
- 08 Jan 2023 This trial has been completed in Netherlands (End Date: 1 Dec 2022) according to European Clinical Trials Database record.